Comparison between obese and non-obese nonalcoholic fatty liver disease

被引:30
作者
Chan, Wah-Kheong [1 ]
机构
[1] Univ Malaya, Fac Med, Dept Med, Gastroenterol & Hepatol Unit, Kuala Lumpur 50603, Malaysia
关键词
Nonalcoholic fatty liver disease; Non-obese; Lean; CONFERS SUSCEPTIBILITY; HISTOLOGICAL SEVERITY; ASIAN POPULATION; LEAN PATIENTS; RISK-FACTORS; PNPLA3; GENE; PREVALENCE; ASSOCIATION; FIBROSIS; VARIANT;
D O I
10.3350/cmh.2022.0350
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions that are characterized by excess accumulation of fat in the liver, and is diagnosed after exclusion of significant alcohol intake and other causes of chronic liver disease. In the majority of cases, NAFLD is associated with overnutrition and obesity, although it may be also found in lean or non-obese individuals. It has been estimated that 19.2% of NAFLD patients are lean and 40.8% are non-obese. The proportion of patients with more severe liver disease and the incidence of all- cause mortality, liver-related mortality, and cardiovascular mortality among non- obese and obese NAFLD patients varies across studies and may be confounded by selection bias, underestimation of alcohol intake, and unaccounted weight changes over time. Genetic factors may have a greater effect towards the development of NAFLD in lean or non-obese individuals, but the effect may be less pronounced in the presence of strong environmental factors, such as poor dietary choices and a sedentary lifestyle, as body mass index increases in the obese state. Overall, non-invasive tests, such as the Fibrosis-4 index, NAFLD fibrosis score, and liver stiffness measurement, perform better in lean or non-obese patients compared to obese patients. Lifestyle intervention works in non-obese patients, and less amount of weight loss may be required to achieve similar results compared to obese patients. Pharmacological therapy in non- obese NAFLD patients may require special consideration and a different approach compared to obese patients.
引用
收藏
页码:S58 / S67
页数:10
相关论文
共 55 条
[1]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[2]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690
[3]   Sarcopenia in Hiding: The Risk and Consequence of Underestimating Muscle Dysfunction in Nonalcoholic Steatohepatitis [J].
Bhanji, Rahima A. ;
Narayanan, Praveena ;
Allen, Alina M. ;
Malhi, Harmeet ;
Watt, Kymberly D. .
HEPATOLOGY, 2017, 66 (06) :2055-2065
[4]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[5]   The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD [J].
Carter, Anna ;
Brackley, Simon Mark ;
Gao, Jiali ;
Mann, Jake Peter .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :142-150
[6]   Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease [J].
Chan, Wah-Kheong ;
Tan, Soek-Siam ;
Chan, Siew-Pheng ;
Lee, Yeong-Yeh ;
Tee, Hoi-Poh ;
Mahadeva, Sanjiv ;
Goh, Khean-Lee ;
Ramli, Anis Safura ;
Mustapha, Feisul ;
Kosai, Nik Ritza ;
Raja Ali, Raja Affendi .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (05) :795-811
[7]   Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis [J].
Chan, Wah-Kheong ;
Treeprasertsuk, Sombat ;
Goh, George Boon-Bee ;
Fan, Jian-Gao ;
Song, Myeong Jun ;
Charatcharoenwitthaya, Phunchai ;
Duseja, Ajay ;
Dan, Yock-Young ;
Imajo, Kento ;
Nakajima, Atsushi ;
Ho, Khek-Yu ;
Goh, Khean-Lee ;
Wong, Vincent Wai-Sun .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (12) :2570-+
[8]   A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis [J].
Chan, Wah-Kheong ;
Mustapha, Nik Raihan Nik ;
Mahadeva, Sanjiv .
HEPATOLOGY INTERNATIONAL, 2015, 9 (04) :594-602
[9]   Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males [J].
Chan, Wah-Kheong ;
Bahar, Norhaniza ;
Razlan, Hamizah ;
Vijayananthan, Anushya ;
Sithaneshwar, Pavai ;
Goh, Khean-Lee .
HEPATOLOGY INTERNATIONAL, 2014, 8 (01) :121-127
[10]   Non-alcoholic fatty liver disease in diabetics - prevalence and predictive factors in a multiracial hospital clinic population in Malaysia [J].
Chan, Wah-Kheong ;
Tan, Alexander Tong-Boon ;
Vethakkan, Shireene Ratna ;
Tah, Pei-Chien ;
Vijayananthan, Anushya ;
Goh, Khean-Lee .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (08) :1375-1383